Revenue → Gross profit: $16.4BPharmaceutical → Revenue: $13.4BRevenue → Cost of revenue: $8.4BMedical devices → Revenue: $7.5BOperating profit → Other expenses: $7.2BGross profit → Operating profit: $6.5BGross profit → SG&A: $6.1BImmunology → Pharmaceutical: $4.1BOncology → Pharmaceutical: $4.1BConsumer health → Revenue: $3.9BGross profit → R&D: $3.6BSurgery → Medical devices: $2.4BOrthopaedics → Medical devices: $2.2BNeuroscience → Pharmaceutical: $1.8BInfectious diseases → Pharmaceutical: $1.6BInterventional → Medical devices: $1.5BVision → Medical devices: $1.3BOther pharma → Pharmaceutical: $0.9BPulmonary → Pharmaceutical: $0.9BLoss before taxes → Operating profit: $0.7BTax benefit → Loss before taxes: $0.7BGross profit → Restructuring: $0.1BNet loss → Loss before taxes: $0.1BGross profit → In-process R&D: $0.0BInterest income → Operating profit: $0.0BConsumer health: $3.9BRevenue: $24.7BImmunology: $4.1BPharmaceutical: $13.4BInfectious diseases: $1.6BNeuroscience: $1.8BOncology: $4.1BPulmonary: $0.9BOther pharma: $0.9BMedical devices: $7.5BInterventional: $1.5BOrthopaedics: $2.2BSurgery: $2.4BVision: $1.3BGross profit: $16.4BCost of revenue: $8.4BSG&A: $6.1BR&D: $3.6BIn-process R&D: $0.0BRestructuring: $0.1BOperating profit: $7.2BOther expenses: $7.2BNet loss: $0.1BLoss before taxes: $0.7BInterest income: $0.0BTax benefit: $0.7Bcreated with SankeyArt.comConsumer health$3.9BRevenue$24.7B6% Y/YImmunology$4.1B-0% Y/YPharmaceutical$13.4B4% Y/YInfectious diseases$1.6BNeuroscience$1.8BOncology$4.1BPulmonary$0.9BOther pharma$0.9BMedical devices$7.5B7% Y/YInterventional$1.5BOrthopaedics$2.2BSurgery$2.4BVision$1.3BGross profit$16.4B3% Y/YCost of revenue$8.4B10% Y/YSG&A$6.1B3% Y/YR&D$3.6B3% Y/YIn-process R&D$49M-92% Y/YRestructuring$0.1B86% Y/YOperating profit$7.2BOther expenses$7.2BNet loss$68MLoss before taxes$0.7BInterest income$20MTax benefit$0.7BJohnson & Johnson Q1 FY23 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3